



20th Annual Meeting of the GU Medical Oncologists of Canada (GUMOC)

Friday June 27, 2025 - 08:00-16:30 ET



Westin Hotel, Ottawa | GOVERNOR GENERAL 1-2 | LEVEL 4



27 FRI



07:30 - 09:00	GUMOC Registration & Hot breakfast
	CUA Educational Session #2
08:00 - 08:50	Advanced Bladder Cancer GOVERNOR GENERAL 1-2 LEVEL 4 *Pre-registration recommended - seats are limited.

Meeting Chairs: Michael Ong, Ana Beltran-Bless and Dominick Bossé

09:05 - 09:10 Meeting Introduction

Srikala Sridhar + Meeting Chairs Technical startup – POLL-EV login

Welcome & Opening remarks

SESSION 1 | Hot GU Topics & Crowdsourcing Solutions

Moderators: Jeffrey Graham, Lori Wood

Discussion/Q&A

09:10 - 09:20 Which patient should we be choosing for radioligand therapy, given that it is a highly limited resource in Canada?

Lillian Hanna

09:30 - 09:40 Muscle-invasive bladder cancer post Cis-Gem-Durvalumab or (in the future) EV-Pembrolizumab: What do we do with patients with complete clinical response who refuse surgery?

David Maj

09:40 - 09:50 Discussion/Q&A

09:00 - 09:05

09:20 - 09:30

09:50 - 10:00 How can we leverage and work together in Canada on results of

large gene sequencing panels in common and rare

GU malignancies?

Guliz Ozgun

10:00 - 10:10 Discussion/Q&A

10:10 - 10:30 Practice Sharing across Canada

Christina Canil, Neil Reaume

10:30 - 10:45 Networking Health Break

JUNE 27 FRI

SESSION 2 | Radioligand Therapy in Prostate Cancer

Moderators: Ali Fawaz, April Rose

10:45 - 11:05 KEYNOTE SPEAKER: How do we deliver value now and in the future

for prostate cancer patients with RLT?

Tanya Dorff

11:05 - 11:15 Discussion/Q&A

11:15 - 11:50 Introduction and Pre-Debate Vote

PRO: In ARPI-exposed mCRPC patients, ARPI should ALWAYS be

continued at the same time as Ra223 and PSMA-Lu177

Cristiano Ferrario

CON: In ARPI-exposed mCRPC patients, ARPI should NEVER be

continued at the same time as Ra223 and PSMA-Lu177

Scott North

Questions, Concluding remarks and Post-Debate Vote

11:50 - 12:05 How should we develop more personalized approaches to mCSPC

treatment (de)intensification?

Daniel Khalaf

12:05 - 13:00 Group photo and networking lunch

SESSION 3 | Immunotherapy and Therapeutic Targets in Prostate Cancer

Moderators: Urban Emmenegger, Zineb Hamilou

13:00 - 13:20 Is there a future where more patients with prostate cancer patients

receive immunotherapy?

Tanya Dorff

13:20 - 13:30 Discussion/Q&A

13:30 - 13:45 PARP inhibitors for prostate cancer: Few, many or all?

Kim Chi

13:45 - 13:55 Discussion/Q&A

13:55 - 14:05 Can we successfully roll out T-Cell engagers programs for GU

research in Canada?

Michael Ong

14:05 - 14:15 Discussion/Q&A

14:15 - 14:25 Networking Health Break

JUNE **27** FRI

SESSION 4 | The Evolving Landscape of Bladder and Kidney Cancer

Moderators: Ana-Beltran Bless, Aly-Khan Lalani

14:25 - 14:55 Introduction and Pre-Debate Vote

PRO: Platinum chemotherapy is an important option post-EV Pembro

Nimira Alimohamed (10 min)

CON: Platinum chemotherapy is NOT an important option post-EV

Pembro

Karine Tawagi (10 min)

Concluding remarks and Post-Debate Vote

14:55 - 15:05 When and how to successfully deliver FGFR inhibitors in metastatic

urothelial carcinoma.

Bernie Eigl

15:05 - 15:15 Discussion/Q&A

15:15 - 15:25 Practical Considerations for Toxicity Management of Belzutifan,

Erdafitinib, and Enfortumab

Maria Jiang, Ramy Saleh

15:25 - 15:35 Discussion/Q&A

15:35 - 16:00 CANADIAN TRIVIA GAME SHOW

Host: Rodney Breau
East vs West Canada

16:00 - 16:30 GUMOC Business Meeting

CUA Educational Session #3

16:30 - 17:30 Prostate Cancer

GOVERNOR GENERAL 1-2 | LEVEL 4

*Pre-registration recommended - seats are limited.

19:00 Private networking event for GUMOC members and faculty only.

GOLD SPONSORS





















SILVER SPONSORS











This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the CUA. You may claim a maximum of 6.5 hours of credit.